Therapie der Herzinsuffizienz mit β-Rezeptorenblockern

Literatur

• 1 Asai K, Yang G P, Geng Y J. et al . β-Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gsa mouse.  J Clin Invest. 1999;  104 551-558
• 2 Australia-New Zeeland Heart Failure Research Collaborative Group . Effects of Carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease.  Circulation. 1995;  92 212-218
• 3 Australia-New Zeeland Heart Failure Research Collaborative Group . Randomised, placebo-controlled trial of Carvedilol in patients with congestive heart failure due to ischemic heart disease.  Lancet. 1997;  349 375-380
• 4 Beta-Blocker Evaluation of Survival Trial Investigators . A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure.  N Engl J Med. 2001;  344 1659-1667
• 5 Böhm M. et al . Increase of Giα in human hearts with dilated but not ischemic cardiomyopathy.  Circulation. 1990;  82 1249-1265
• 6 Böhm M, Mittmann C, Schwinger R HG, Erdmann E. Effects of xamoterol on inotropic and lusitropic properties of the human myocardium and on adenylate cyclase activity.  Am Heart J. 1990;  120 1381-1392
• 7 Bristow M R. et al . β-Adrenergic Receptor Blockade in Chronic Heart Failure.  Circulation. 2000;  101 558-569
• 8 Bristow M R, Gilbert E M, Abraham W T. et al . Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure.  Circulation. 1996;  94 2807-2816
• 9 Bristow M R, O`Connell J B, Gilbert E M. et al. for the Bucindolol Investigators . Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy.  Circulation. 1994;  89 1632-1642
• 10 Bristow M R. Changes in myocardial and vascular receptors in heart failure.  J Am Coll Cardiol. 1993;  22 (Suppl A) 61A-71A
• 11 Bristow M R. Mechanism of action of beta-blocking agents in heart failure.  Am J Cardiol. 1997;  80 26L-40L
• 12 Brixius K. et al . Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium.  Br J Pharmacol. 2001;  133 1330-1338
• 13 Bundkirchen A. et al . Bucindolol Exerts Agonistic Activity on the Propranolol-Insensitive State of β₁-Adrenoceptors in Human Myocardium.  JPET. 2002 (in press); 
• 14 Campbell D J. et al . β-blockers, angiotensin II, and ACE inhibitors in patients with heart failure.  Lancet. 2001;  358 1609-1610
• 15 CIBIS-II Investigators and Committees . The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.  Lancet. 1999;  353 9-13
• 16 CIBIS-Investigators and Committees . A randomized trial of beta-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS).  Circulation. 1994;  90 : 1 765-1733
• 17 Cohn J N. et al . A Randomized Trial of the Angiotensin-Receptor-Blocker Valsartan in Chronic Heart Failure.  N Engl J Med. 2001;  354 1667-1675
• 18 Cohn J N. et al . Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.  N Engl J Med. 1984;  311 822
• 19 Cohn J N, Fowler M B, Bristow M R. et al., for Carvedilol Heart Failure Study Group . Effect of Carvedilol in severe chronic heart failure.  J Am Coll Cardiol (Abstract). 1996;  27 169 A
• 20 Colucci W S, Packer M, Bristow M R. et al., for the US Carvedilol Heart Failure Study Group . Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure.  Circulation. 1996;  94 2800-2806
• 21 Communal C, Singh K, Sawyer D B. et al . Opposing Effects of β₁- and β₂-Adrenergic Receptors on Cardiac Myocyte Apoptosis. Role of a Pertussis Toxin-Sensitive G Protein.  Circulation. 1999;  100 2210-2212
• 22 D¿Angelo. et al . Transgenic G_{a q} overexpression induces cardiac contractile failure in mice.  Proc Natl Acad Sci USA. 1997;  94 8121-8126
• 23 Engelhardt S. et al . Progressive hypertrophy and heart failure in β1adrenergic receptor transgenic mice.  Proc Natl Acad Sci U S A. 1999;  96 7059-7064
• 24 Erdmann E, Lechat P, Verkenne P. et al . Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure.  Eur J Heart Fail. 2001;  3 469-479
• 25 Gauthier C. et al . Functional β3-adrenoceptor in the human heart.  J Clin Invest. 1996;  98 556-562
• 26 Geng Y J. et al . Overexpression of Gsa accelerates programmed death (apoptosis) of myocardiocytes in transgenic mice.  Circulation (Abstract). 1996;  94 (Suppl I) I-1640
• 27 Gilbert E M, Olsen S L, Renlund D G. et al . Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy.  Am J Cardiol. 1993;  71 23C-29C
• 28 Gilbert E M. et al . Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart.  Circulation. 1996;  94 2817-2825
• 29 Hall S A. et al . Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with β-adrenergic blockade.  J Am Coll Cardiol. 1995;  25 1154-116
• 30 Hoppe U C, Erdmann E. Leitlinien zur Therapie der chronischen Herzinsuffizienz.  Z Cardiol. 2001;  90 218-237
• 31 Iwase M. et al . Adverse effects of chronic endogenous sympathetic drive induced by cardiac G_{a s} Overexpression.  Circ Res. 1996;  78 517-524
• 32 Kaumann A J. et al . Modulation of human cardiac function through 4 beta-adrenergic populations.  Naunyn Schmiedebergs Arch Pharmacol. 1997;  355 667-681
• 33 Kubo H. et al . Patients With End-Stage Congestive Heart Failure Treated With β-Adrenergic Receptor Antagonists Have Improved Ventricular Myocyte Calcium Regulatory Protein Abundance.  Circulation. 2001;  104 1012-1018
• 34 Lechat P. et al . Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency.  Bisoprolol Study (CIBIS) Circulation. 1997;  96 2197-2205
• 35 Lowes B D. et al . The effect of carvedilol on left ventricular mass, chamber geometry and mitral regurgitation in chronic heart failure.  Am J Cardiol. 1999;  83 1201-1205
• 36 Maack C. et al . Characterization of beta(1)-selectivity, adrenoceptor-G(s)-protein interaction and inverse agonism of nebivolol in human myocardium.  Br J Pharmacol. 2001;  132 1817-1826
• 37 MERIT-HF Study Group . Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF).  Lancet. 1999;  353 2001-2006
• 38 Nicholas G, Oakley C, Pouleur H. et al . Xamoterol in severe heart failure.  Lancet. 1990;  336 1-6
• 39 Packer M. et al . Effct of Carvedilol on Survival in Severe Chronic Heart Failure.  N Engl J Med. 2001;  344 1651-1658
• 40 Packer M, Colucci W S, Sackner-Bernstein J D. et al., for the PRECISE Study group . Double-blind, placebo-controlled study of the effects of Carvedilol in patients with moderate to severe heart failure: the PRECISE trial.  Circulation. 1996;  94 2793-2799
• 41 Pauwels P J, Van Gompel P, Leysen J E. Human beta 1- and beta 2-adrenergic receptor binding and mediated accumulation of cAMP in transfected Chinese hamster ovary cells. Profile of Nebivolol and known beta-adrenergic blockers.  Biochem Pharmacol. 1991;  42 1683-1689
• 42 Port J D. et al . Echocardiographic and histopathological characterization of young and old transgenic mice over-expressing the human β_b1-adrenergic receptor.  J Am Coll Cardiol (Abstract). 1998;  31 177A (Suppl A)
• 43 Schwinger R HG. et al . Different β-adrenoceptor-effector coupling in human ventricular and atrial myocardium.  Eur J Clin Invest. 1991;  21 443-451
• 44 Schwinger R HG. et al . Effect of inotropic stimulation on the negative force-frequency-relationship in the failing human heart.  Circulation. 1993;  88 2267-2276
• 45 Schwinger R HG. et al . Evidence against spare or uncoupled β-adrenoceptors in the human heart.  Am Heart. 1990;  119 899-904
• 46 Schwinger R HG. et al . Inotropic and lusitropic dysfunction in myocardium from patients with dilated cardiomyopathy.  Am Heart J. 1992;  123 116-128
• 47 Schwinger R HG. et al . Reduced Ca²⁺-Sensitivity of SERCA 2a in Failing Human Myocardium due to Reduced Serin-16 Phospholamban Phosphorylation.  J Mol Cell Cardiol. 1999;  31 479-491
• 48 Schwinger R HG. et al . The effect of xamoterol in failing human myocardium.  Eur Heart. 1990;  11 323-327
• 49 Schwinger R HG. et al . Therapie der chronischen Herzinsuffizienz mit β-Rezeptorenblockern?.  Deut Med Wochenschr. 1990;  115 825-831
• 50 Schwinger R HG. Therapie der Herzinsuffizienz - State of the Art.  Medizin im Bild. 2000;  6 35-41
• 51 Talwar K K. et al . Hemodynamic predctors of early intolerance and long-term effects of propanolol in dilated cardiomyopathy.  J Card Fail. 1996;  2 273-277
• 52 Ungerer M. et al . Expression of β-arrestins an β-adrenergic receptor kinases in the failing human heart.  Circ Res. 1994;  74 206-213
• 53 Van de Water A, Janssens W, Van Neulen J. et al . Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist.  J Cardiovasc Pharmacol. 1988;  11 552-63
• 54 Waagstein F. et al . A long-term beta-blockade in dilated cardiomyopathy. Effekts of short- and long-term metoprolol treatment followed by withdrawal and readmisnitration of metoprolol.  Circulation. 1989;  80 551-563
• 55 Waagstein F, Bristow M R, Swedberg K. et al . Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy.  Lancet. 1993;  342 1441-1446
• 56 Wisenbaugh T. et al . Long-term (3 month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathie.  J Am Coll Cardiol. 1993;  21 1094-1100

Korrespondenz